BioWave provides FDA‑cleared, high‑frequency neurostimulation devices that deliver non‑invasive electrical signals through the skin to block pain nerve transmission, offering drug‑free relief for acute and chronic pain. Its product line includes a portable home unit, a clinician‑supervised in‑office system, and a quick‑treatment pen, each capable of delivering up to 72 hours of analgesia from a single 30‑minute session and reducing reliance on medication.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with acute or chronic pain often rely on medications, invasive procedures, or bulky clinical devices that can cause side effects, require surgery, or limit accessibility, leading to inadequate pain control and reduced quality of life.
Solution
BioWave offers FDA‑cleared, high‑frequency neurostimulation devices that deliver non‑invasive electrical signals through the skin to block pain nerve transmission at its source. The technology is available in several form factors—including a portable home unit, a clinician‑supervised in‑office system, and a quick‑treatment pen—allowing treatment in clinics, veterans’ facilities, sports settings, or at home. A single 30‑minute session can provide up to 72 hours of relief, and repeated use yields cumulative benefits without drugs, implants, or surgery. Clinical studies demonstrate significant pain score reductions, improved mobility, and decreased reliance on pain medication. Devices integrate with existing care pathways and can be reimbursed through workers’ compensation, personal injury, auto insurance, or veteran health programs.
Target Audience
Primary customers are healthcare providers—including physicians, pain clinics, veteran health systems, and sports medicine teams—who need drug‑free pain relief solutions, as well as individual patients seeking at‑home management of chronic or acute pain.
Features
- Patented high‑frequency neurostimulation that penetrates deeper than conventional TENS, directly inhibiting action potentials in peripheral pain nerves
- Multiple device options: BioWavePRO (clinical), BioWaveHOME (home use), BioWaveGO (portable), and BioWavePENS (in‑office 30‑min procedure)
- FDA‑cleared, non‑invasive electrodes (surface and percutaneous) for targeted treatment of specific pain sites
- Single 30‑minute session delivers up to 72 hours of analgesia; repeated sessions build cumulative pain reduction
- Portable, battery‑operated units enable use in clinics, veterans’ hospitals, sports facilities, or patient homes
- Clinical evidence base with peer‑reviewed studies showing average 3.5‑point reduction on a 0‑10 pain scale and high patient satisfaction
- Compatibility with insurance reimbursement streams (Workers’ Compensation, Personal Injury, Auto, VA) for covered use